Genetic variability of hepatitis C virus (HCV) 5′ untranslated region in HIV/HCV coinfected patients treated with pegylated interferon and ribavirin

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Bukowska Ośko, Iwona ^a   Pawełczyk, Agnieszka ^a   Perlejewski, Karol ^a   Kubisa, Natalia ^a   Cortés, Kamila Caraballo ^a   Rosińska, Magdalena ^b   Płoski, Rafał ^a   Fic, Maria ^a   Kaźmierczak, Justyna ^a   Popiel, Marta ^a   Ząbek, Piotr ^c   Horban, Andrzej ^c   Radkowski, Marek ^a   Laskus, Tomasz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL INSTITUTE OF HYGIENE   (Poland)

^c SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; 5' UNTRANSLATED REGION; ALPHA INTERFERON; ANTIVIRUS AGENT; INTERLEUKIN DERIVATIVE;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG USE; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; MIXED INFECTION; MOLECULAR CLONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT OUTCOME; VIRUS STRAIN; COINFECTION; DRUG EFFECTS; GENETIC VARIATION; GENETICS; HEPACIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; VIROLOGY; YOUNG ADULT;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

5' UNTRANSLATED REGIONS; ADULT; ANTIVIRAL AGENTS; BASE SEQUENCE; COINFECTION; FEMALE; GENETIC VARIATION; HEPACIVIRUS; HIV; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RIBAVIRIN; SEQUENCE ALIGNMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928795233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125604     Document Type: Article

References (40)

1. van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chene G, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology. 2013; 144 (4):751-60 e2. doi: 10.1053/j.gastro.2012.12.026 PMID: 23266560.
2. Wandeler G, Gsponer T, Bregenzer A, Gunthard HF, Clerc O, Calmy A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2012; 55(10):1408-16. doi: 10.1093/cid/cis694 PMID: 22893583.
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4):1333-42. doi: 10.1002/hep.26141 PMID: 23172780.
4. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. International journal of epidemiology. 2005; 34(1):121-30. doi: 10.1093/ije/dyh307 PMID: 15561752.
5. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV medicine. 2013; 14(4):195-207. doi: 10.1111/j.1468-1293.2012.01051.x PMID: 22998068.
6. Ananthakrishnan AN, McGinley EL, Fangman J, Saeian K. Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. Journal of viral hepatitis. 2010; 17 (10):720-9. doi: 10.1111/j.1365-2893.2009.01232.x PMID: 20002558.
7. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. The Lancet Infectious diseases. 2004; 4(7):437-44. doi: 10.1016/S1473-3099(04)01059-X PMID: 15219554.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England journal of medicine. 2004; 351(5):438-50. doi: 10.1056/NEJMoa040842 PMID: 15282351.
9. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. Journal of virology. 2005; 79(5):3071-83. doi: 10.1128/JVI.79.5.3071-3083.2005 PMID: 15709027; PubMed Central PMCID: PMC548442.
10. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, Arias A. Viruses as quasispecies: biological implications. Current topics in microbiology and immunology. 2006; 299:51-82. PMID: 16568896.
11. Biebricher CK, Eigen M. The error threshold. Virus research. 2005; 107(2):117-27. doi: 10.1016/j.virusres.2004.11.002 PMID: 15649558.
12. Laskus T, Wang LF, Radkowski M, Vargas H, Nowicki M, Wilkinson J, et al. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. Journal of virology. 2001; 75(5):2059-66. doi: 10.1128/JVI.75.5.2059-2066.2001 PMID: 11160710; PubMed Central PMCID: PMC114790.
13. Feliu A, Gay E, Garcia-Retortillo M, Saiz JC, Forns X. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2004; 10(9):1131-9. doi: 10.1002/lt.20206 PMID: 15350003.
14. Flint SJ. Principles in Virology: Molecular Biology, Pathogenesis, and Control of Animal Viruses. ASM Press 2004.
15. Quesnel-Vallieres M, Lemay M, Lapointe N, Martin SR, Soudeyns H. HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2008; 43(2):236-40. doi: 10.1016/j.jcv.2008.06.019 PMID: 18707918.
16. Sherman KE, Rouster SD, Stanford S, Blackard JT, Shire N, Koziel M, et al. Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. The Journal of infectious diseases. 2010; 201(5):712-9. doi: 10.1086/650490 PMID: 20105080; PubMed Central PMCID: PMC2827649.
17. Bukowska-Osko I, Radkowski M, Pawelczyk A, Rosinska M, Caraballo Cortes K, Ploski R, et al. Hepatitis C virus 5′ untranslated region variability correlates with treatment outcome. Journal of viral hepatitis. 2014; 21(8):551-9. doi: 10.1111/jvh.12182 PMID: 24118647.
18. Khaliq S, Latief N, Jahan S. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. Archives of virology. 2014; 159(1):1-15. doi: 10.1007/s00705-013-1780-x PMID: 23851652.
19. Lara J, Khudyakov Y. Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance. Antiviral therapy. 2012; 17(7 Pt B):1471-5. doi: 10.3851/IMP2478 PMID: 23321567.
20. Laskus T, Radkowski M, Wang LF, Nowicki M, Rakela J. Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication. Journal of virology. 2000; 74(2):1014-7. PMID: 10623766; PubMed Central PMCID: PMC111624.
21. Laskus T, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M, et al. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology. 2004; 127(3):764-76. PMID: 15362033.
22. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular biology and evolution. 2011; 28(10):2731-9. doi: 10.1093/molbev/msr121 PMID: 21546353; PubMed Central PMCID: PMC3203626.
23. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. Journal of virology. 2004; 78(11):5867-74. doi: 10.1128/JVI.78.11.5867-5874.2004 PMID: 15140984; PubMed Central PMCID: PMC415836.
24. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005; 41(1):106-14. doi: 10.1002/hep.20518 PMID: 15619235.
25. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(5):3081-6. doi: 10.1073/pnas.052712599 PMID: 11880647; PubMed Central PMCID: PMC122476.
26. Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, Osaki Y, et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PloS one. 2011; 6(9):e24907. doi: 10.1371/journal.pone.0024907 PMID: 21966381; PubMed Central PMCID: PMC3178558.
27. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science. 2000; 288(5464):339-44. PMID: 10764648.
28. Bolcic F, Sede M, Moretti F, Westergaard G, Vazquez M, Laufer N, et al. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Archives of virology. 2012; 157(4):703-11. doi: 10.1007/s00705-012-1230-1 PMID: 22270759.
29. Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, et al. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. Journal of medical virology. 2004; 74(1):41-53. doi: 10.1002/jmv.20144 PMID: 15258967.
30. Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ. Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virology journal. 2008; 5:78. doi: 10.1186/1743-422X-5-78 PMID: 18613968; PubMed Central PMCID: PMC2483966.
31. Xu Z, Fan X, Xu Y, Di Bisceglie AM. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. Journal of virology. 2008; 82(19):9417-24. doi: 10.1128/JVI.00896-08 PMID: 18667493; PubMed Central PMCID: PMC2546966.
32. El Awady MK, Azzazy HM, Fahmy AM, Shawky SM, Badreldin NG, Yossef SS, et al. Positional effect of mutations in 5′UTR of hepatitis C virus 4a on patients' response to therapy. World journal of gastroenterology: WJG. 2009; 15(12):1480-6. PMID: 19322922; PubMed Central PMCID: PMC2665143.
33. Soler M, Pellerin M, Malnou CE, Dhumeaux D, Kean KM, Pawlotsky JM. Quasispecies heterogeneity and constraints on the evolution of the 5′ noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy. Virology. 2002; 298(1):160-73. PMID: 12093183.
34. Katano Y, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, et al. Association with 5′-untranslated region and response to interferon in chronic hepatitis C. Hepato-gastroenterology. 2007; 54(75):854-7. PMID: 17591078.
35. Zekri AR, El-Din HM, Bahnassy AA, Khaled MM, Omar A, Fouad I, et al. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virology journal. 2007; 4:16. doi: 10.1186/1743-422X-4-16 PMID: 17300723; PubMed Central PMCID: PMC1805740.
36. Ni YH, Chang MH, Chen PJ, Hsu HY, Lu TW, Lin KH, et al. Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation. Journal of medical virology. 1999; 58(2):132-8. PMID: 10335860.
37. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology. 1998; 27(1):223-7. doi: 10.1002/hep.510270134 PMID: 9425941.
38. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. Journal of hepatology. 1997; 26(5):975-82. PMID: 9186827.
39. Gallegos-Orozco JF, Arenas JI, Vargas HE, Kibler KV, Wilkinson JK, Nowicki M, et al. Selection of different 5′ untranslated region hepatitis C virus variants during post-transfusion and post-transplantation infection. Journal of viral hepatitis. 2006; 13(7):489-98. doi: 10.1111/j.1365-2893.2006.00724.x PMID: 16792543.
40. Laskus T, Wang LF, Rakela J, Vargas H, Pinna AD, Tsamandas AC, et al. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology. 1996; 220(1):171-6. doi: 10.1006/viro.1996.0297 PMID: 8659109.